Clinical Trials Logo

Head and Neck Neoplasms clinical trials

View clinical trials related to Head and Neck Neoplasms.

Filter by:

NCT ID: NCT00040807 Completed - Clinical trials for Head and Neck Cancer

Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer

Start date: November 19, 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of irinotecan and docetaxel in treating patients who have metastatic or locally recurrent head and neck cancer.

NCT ID: NCT00038584 Completed - Clinical trials for Carcinoma, Squamous Cell

A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer

Start date: June 1999
Phase: Phase 1
Study type: Interventional

SCH66336 is a drug that has been designed to block the growth of tumor cells and encourage tumor cell death. This is a randomized study where patients will receive study drug or no drug. Participants in this study are scheduled to have surgery to remove head and neck cancer.

NCT ID: NCT00038038 Withdrawn - Clinical trials for Head and Neck Neoplasms

Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole

Start date: January 1994
Phase: N/A
Study type: Interventional

The purpose of this clinical research study is to answer the following questions using 18F-fluoromisonidazole as an imaging agent: 1. Do cells exist in human tumors that are at very low oxygen levels (hypoxic cells)? 2. If hypoxic cells exist in human tumors, do they effect the ability of radiotherapy to control human tumors? 3. Can Positron Emission Tomography (PET scanning) detect hypoxic cells in human tumors?

NCT ID: NCT00036881 Completed - Clinical trials for Head and Neck Cancer

Zinc Sulfate in Preventing Loss of Sense of Taste in Patients Undergoing Radiation Therapy for Head and Neck Cancer

Start date: May 2002
Phase: Phase 3
Study type: Interventional

RATIONALE: It is not yet known whether zinc sulfate is effective in preventing the loss of ability to taste food in cancer patients who are undergoing radiation therapy for head and neck cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of zinc sulfate in preventing loss of sense of taste in patients who are undergoing radiation therapy for head and neck cancer.

NCT ID: NCT00036790 Completed - Breast Cancer Clinical Trials

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

Start date: February 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining motexafin gadolinium with doxorubicin in treating patients who have recurrent or metastatic cancer.

NCT ID: NCT00033618 Completed - Tongue Cancer Clinical Trials

Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck

Start date: November 2002
Phase: Phase 2
Study type: Interventional

Randomized phase II trial to study the effectiveness of ixabepilone in treating patients who have metastatic or recurrent head and neck cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

NCT ID: NCT00030576 Completed - Clinical trials for Head and Neck Cancer

Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Start date: November 2001
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with cisplatin may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining erlotinib and cisplatin in treating patients who have recurrent or metastatic head and neck cancer.

NCT ID: NCT00028405 Completed - Breast Cancer Clinical Trials

Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors

Start date: November 2001
Phase: Phase 1
Study type: Interventional

This multi-center photodynamic therapy study plans to treat patients with large tumors in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis. The treatment is limited to patients that have failed to respond to currently approved methods of treatment. The study involves a single, intravenous administration of an investigational drug, LS11 (previously studied in approximately 80 cancer patients) and the placement of a novel, flexible light delivery catheter inside the tumor by a minor surgical procedure. The activation of LS11 by the light delivery catheter over a period of 1-24 hrs may result in destruction of tumor tissue.

NCT ID: NCT00027534 Completed - Breast Cancer Clinical Trials

Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer

Start date: January 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from a person's white blood cells that have been treated in the laboratory may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced or metastatic cancer.

NCT ID: NCT00026533 Completed - Clinical trials for Head and Neck Cancer

Thalidomide in Treating Patients With Thyroid Cancer

Start date: June 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Thalidomide may stop the growth of thyroid cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness thalidomide in treating patients who have thyroid cancer.